Dr. Roberto Pili, MD
Claim this profileIndiana University/ Melvin and Bren Simon Cancer Center
Studies Cancer
Studies Prostate Cancer
7 reported clinical trials
19 drugs studied
Area of expertise
1Cancer
Stage IV
Stage III
2Prostate Cancer
Affiliated Hospitals
Clinical Trials Roberto Pili, MD is currently running
Immunotherapy + Chemotherapy
for Bladder Cancer
Upon successful screening and registration, enrollment to durvalumab monotherapy (cohort 1) will begin. If DLT criteria outlined in the protocol are exceeded with durvalumab monotherapy (cohort 1), the study will close. Provided the safety of durvalumab monotherapy is established, enrollment to combination regimen cohorts will proceed. Cohorts will simultaneously enroll in parallel to each other with patients assigned to cohorts based on patient slot availability and study site choice of radiation arm participation. Patient assignment to future phase 1 arms would proceed similarly. Within BCG-containing cohorts, treatment will begin at full-dose BCG. If DLT criteria outlined in Section 5.1.4 are exceeded with full-dose BCG, a one level dose reduction of BCG will be implemented. If DLT criteria outlined in Section 5.1.4 are exceeded with reduced-dose BCG, the BCG-containing cohort will not proceed to Phase 2 of the study. Similarly, if DLT criteria outlined in Section 5.1.4 are exceeded within non-BCG containing cohorts, the non-BCG containing cohort will not proceed to phase 2 of the study. Due to the prolonged half-life of antibody therapies, no dose adjustments are planned for durvalumab in any of the cohorts.
Recruiting1 award Phase 1 & 26 criteria
Radium-223 + Docetaxel
for Prostate Cancer
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.
Recruiting2 awards Phase 323 criteria
More about Roberto Pili, MD
Clinical Trial Related6 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Roberto Pili, MD has experience with
- Docetaxel
- Gemcitabine
- Tremelimumab
- Durvalumab
- External Beam Radiotherapy (EBRT)
- Bacillus Calmette-Guérin (BCG)
Breakdown of trials Roberto Pili, MD has run
Cancer
Prostate Cancer
Bladder Cancer
Transitional Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Roberto Pili, MD specialize in?
Roberto Pili, MD focuses on Cancer and Prostate Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Roberto Pili, MD currently recruiting for clinical trials?
Yes, Roberto Pili, MD is currently recruiting for 5 clinical trials in Indianapolis Indiana. If you're interested in participating, you should apply.
Are there any treatments that Roberto Pili, MD has studied deeply?
Yes, Roberto Pili, MD has studied treatments such as Docetaxel, Gemcitabine, Tremelimumab.
What is the best way to schedule an appointment with Roberto Pili, MD?
Apply for one of the trials that Roberto Pili, MD is conducting.
What is the office address of Roberto Pili, MD?
The office of Roberto Pili, MD is located at: Indiana University/ Melvin and Bren Simon Cancer Center, Indianapolis, Indiana 46202 United States. This is the address for their practice at the Indiana University/ Melvin and Bren Simon Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.